A reconstituted HDL containing V156K or R173C apoA-I exhibited anti-inflammatory activity in apo-E deficient mice and showed resistance to myeloperoxidase-mediated oxidation

Experimental and Molecular Medicine

Volumn 41, Issue 6, 2009, Pages 417-428

  Cho, Kyung Hyun ^a   Kim, Jae Ryong ^a  

^a Yeungnam University   (South Korea)

Author keywords

Apolipoprotein A I; Apolipoproteins E; Atherosclerosis; HDL; Inflammation; Lipoproteins

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; ASPARTATE AMINOTRANSFERASE; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LIPID HYDROPEROXIDE; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN; RECONSTITUTED HIGH DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AORTA SINUS; ARTICLE; ATHEROSCLEROSIS; CHLORINATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; CULTURE MEDIUM; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 3; IMMUNODETECTION; MACROPHAGE; MALE; MOUSE; NITRATION; NONHUMAN; POINT MUTATION; WILD TYPE;

MUS;

EID: 67649653585     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.3858/emm.2009.41.6.047     Document Type: Article

References (34)

1. Alam K, Meidell RS, Spady DK. Effect of up-regulating individual steps in the reverse choleterol transport pathway on reverse cholesterol transport in normolipidemic mice. J Biol Chem 2001;276:15641-15649 (Pubitemid 37391591)
2. Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC. High density lipoprotein function. J Am Coll Cardiol 2005;46:1792-1798
3. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004;95:764-772 (Pubitemid 39390578)
4. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power: the FRAP assay. Anal Biochem 1996;239:70-76 (Pubitemid 126745087)
5. Caraway WT. Determination of uric acid in serum by a carbonate method. Am J Clin Pathol 1955;25:840-845
6. Chiesa G, Monteggia E, Marchesi M, Lonrenzon P, Laucello M, Lorusso V, Di Mario C, Karvouni E, Newton RS, Bisgaier CL, Franceschini G, Sirtori CR. Recombinant apolipoprotein A-IMilano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 2002;90:974-980 (Pubitemid 34633863)
7. Cho KH, Park SH, Han JM, Kim HC, Choi YK, Choi I. ApoA-I mutants V156K and R173C promote anti-inflammatory function and antioxidant activities. Eur J Clin Invest 2006;36:875-882 (Pubitemid 44707087)
8. Cho KH, Park SH, Han JM, Kim HC, Chung YJ, Choi I, Kim JR. A point mutant of apolipoprotein A-I, V156K, exhibited potent anti-oxidant and anti-atherosclerotic activity in hypercholesterolemic C57BL/6 mice. Exp Mol Med 2007;39:160-169 (Pubitemid 46683401)
9. Coutinho TA, Turner ST, Peyser PA, Bielak LF, Sheedy PF, Kullo IJ. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. Am J Hypertens 2007;20:83-89 (Pubitemid 46014067)
10. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994;94:437-444 (Pubitemid 24218123)
11. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126-1138 (Pubitemid 14201166)
12. Fogelman AM. When good cholesterol goes bad. Nature Med 2004;10:902-903 (Pubitemid 39273726)
13. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. Am J Med 1977;62: 707-714
14. Gulledge AA, Mcshea C, Schwartz T, Koch G, Lord ST. Effects of hyperfibrinogenemia on vasculature of C57BL/6 mice with and without atherogenic diet. Arterioscler Thromb Vasc Biol 2003;23:130-135 (Pubitemid 36091637)
15. Han JM, Jeong TS, Lee WS, Choi I, Cho KH. Structural and functional properties of V156K and A158E mutants of apolipoprotein A-I in the lipid-free and lipid-bound states. J Lipid Res 2005;46:589-596 (Pubitemid 43109795)
16. Kaul S, Rukshin V, Santos R, Azarbal B, Bisgaier CL, Johansson J, Tsang VT, Chyu KY, Cercek B, Mirocha J, Shah PK. Intramural delivery of recombinant apolipoprotein A-IMilano/Phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries. Circulation 2003;107:2551-2554 (Pubitemid 36628934)
17. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 2005;4:193-205 (Pubitemid 40372554)
18. Miyazaki A, Sakuma S, Morikawa W, Takiue T, Miake F, Terano T, Sakai M, Hakamata H, Sakamoto Y, Naito M, Ruan Y, Takahashi K, Ohta T, Horiuchi S. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1995;15:1882-1888
19. Nanjee MN, Doran JE, Lerch PG, Miller NE. Acute effects of intravenous infusion of apoA1/phosphatidylcholine discs on plasma lipoprotein in humans. Arterioscler Thromb Vasc Biol 1999;19:979-989 (Pubitemid 29177346)
20. Nanjee MN, Cooke CJ, Garvin R, Semeria F, Lewis G, Olszewski WL, Miller NE. Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res 2001;42:1586-1593 (Pubitemid 33020090)
21. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, Garber D, Fogelman AM. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal. Curr Opin Lipidol 2004;15:645-649 (Pubitemid 39612982)
22. Negre-Salvayre A, Dousset N, Ferretti G, Bacchetti T, Curatola G, Salvayre T. Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radical Biology & Medicine 2006;41:1031-1040 (Pubitemid 44348872)
23. Newton RS, Krause BR. HDL therapy for the acute treatment of atherosclerosis. Atherosclerosis Suppl 2002;3:31-38 (Pubitemid 38234484)
24. Ng CJ, Bourquard N, Hama SY, Shih D, Grijalva VR, Navab M, Fogelman AM, Reddy ST. Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2007;27:1368-1374 (Pubitemid 46809427)
25. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005a;25:1102-1111 (Pubitemid 40776595)
26. Nicholls SJ, Dusting GJ, Cutri B, Bao S, Drummond GR, Rye KA, Barter PJ. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and pro-inflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 2005b;111:1543-1550 (Pubitemid 40470651)
27. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. J Am Med Assoc 2003;290:2292-2300
28. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 1987;68:231-240 (Pubitemid 17159775)
29. Ross R. Atherosclerosis-an inflammatory disease. N Eng J Med 340:115-126
30. Shah PK, Nilsson J, Kaul S, Fishbein MC, Ageland H, Hamsten A, Johansson J, Karpe F, Cercek B. Effects of recombinant apolipoprotein A-IMilano on aortic atherosclerosis in apo-E deficient mice. Circulation 1998;97:780-785 (Pubitemid 28135341)
31. Shah PK, Yano J, Reyes O, Chyu KY, Kaul S, Bisgaier CL, Drake S, Cercek B. High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Circulation 2001;103:3047-3050
32. Shao B, Bergt C, Fu X, Green P, Voss JC, Oda MN, Oram JF, Heinecke JW. Tyr192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport. J Biol Chem 2005;280:5983-5993 (Pubitemid 40280082)
33. Shao B, Oda MN, Bergt C, Fu X, Green P, Brot N, Oram JF, Heinecke JW. Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoproteinA-I. J Biol Chem 2006;281:9001-9004 (Pubitemid 43864611)
34. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodes-Cabau J. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis. J Am Med Assoc 2007:297:1675-1682